Skip to main content
Journal cover image

Retreatment with talimogene laherparepvec for advanced melanoma.

Publication ,  Journal Article
Hu, J; Masoud, SJ; Ravichandran, S; Beasley, GM; Mosca, PJ
Published in: Immunotherapy
November 2020

Aim: Talimogene laherparepvec (T-VEC) is a genetically modified oncolytic herpesvirus approved for the treatment of unresectable, locoregionally advanced and recurrent melanoma. There is little relevant literature in the context of retreatment with T-VEC. Materials & methods: We reviewed four patients aged 71-87 years old with stage IIIB-IV melanoma at treatment who were rechallenged with T-VEC after experiencing recurrence of locoregional disease or prior treatment-limiting toxicity. Results: Cessation of initial treatment was due to one of the following reasons: severe adverse event (one case), mixed response (one case) or complete response (two cases). Three males and one female underwent T-VEC retreatment with a mean of 5.5 injection cycles. Three patients experienced a complete response to retreatment, while one experienced disease progression. Conclusion: Intralesional T-VEC may be effective and well-tolerated in patients who have completed prior T-VEC therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Immunotherapy

DOI

EISSN

1750-7448

Publication Date

November 2020

Volume

12

Issue

16

Start / End Page

1167 / 1172

Location

England

Related Subject Headings

  • Treatment Outcome
  • Retreatment
  • Melanoma
  • Male
  • Humans
  • Herpesvirus 1, Human
  • Female
  • Fatal Outcome
  • Biological Products
  • Antineoplastic Agents, Immunological
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hu, J., Masoud, S. J., Ravichandran, S., Beasley, G. M., & Mosca, P. J. (2020). Retreatment with talimogene laherparepvec for advanced melanoma. Immunotherapy, 12(16), 1167–1172. https://doi.org/10.2217/imt-2020-0029
Hu, Janice, Sabran J. Masoud, Surya Ravichandran, Georgia M. Beasley, and Paul J. Mosca. “Retreatment with talimogene laherparepvec for advanced melanoma.Immunotherapy 12, no. 16 (November 2020): 1167–72. https://doi.org/10.2217/imt-2020-0029.
Hu J, Masoud SJ, Ravichandran S, Beasley GM, Mosca PJ. Retreatment with talimogene laherparepvec for advanced melanoma. Immunotherapy. 2020 Nov;12(16):1167–72.
Hu, Janice, et al. “Retreatment with talimogene laherparepvec for advanced melanoma.Immunotherapy, vol. 12, no. 16, Nov. 2020, pp. 1167–72. Pubmed, doi:10.2217/imt-2020-0029.
Hu J, Masoud SJ, Ravichandran S, Beasley GM, Mosca PJ. Retreatment with talimogene laherparepvec for advanced melanoma. Immunotherapy. 2020 Nov;12(16):1167–1172.
Journal cover image

Published In

Immunotherapy

DOI

EISSN

1750-7448

Publication Date

November 2020

Volume

12

Issue

16

Start / End Page

1167 / 1172

Location

England

Related Subject Headings

  • Treatment Outcome
  • Retreatment
  • Melanoma
  • Male
  • Humans
  • Herpesvirus 1, Human
  • Female
  • Fatal Outcome
  • Biological Products
  • Antineoplastic Agents, Immunological